H.C. Wainwright Reiterates Buy Rating, $21 Price Target on Alpine Immune Sciences (ALPN), "Data Firmly Justify Expliration of davoceticept"
Go back to H.C. Wainwright Reiterates Buy Rating, $21 Price Target on Alpine Immune Sciences (ALPN), "Data Firmly Justify Expliration of davoceticept"| Alpine Management Systems, Inc. (NASDAQ: ALPN) | Delayed: 64.97 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $64.97 | 52 Week High | $0.00 | |||
| Open | $43.88 | 52 Week Low | $2156.81 | |||
| Day High | $64.97 | P/E | N/A | |||
| Day Low | $64.97 | EPS | $0.00 | |||
| Volume | 6,065 | |||||
